KSQ Therapeutics Strengthens Leadership Team with Promotion of Micah Benson, Ph.D., to Senior Vice President, Head of Immunobiology and Andrew Wylie, Ph.D., to Senior Vice President, Head of Oncology

by s2desi5_ksqtherapeutics | Feb 1, 2021 | Uncategorized

CAMBRIDGE, Mass., February 1, 2021- KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced key...

KSQ Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

by s2desi5_ksqtherapeutics | Mar 10, 2021 | Uncategorized

CAMBRIDGE, Mass., March 10, 2021- KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced that the...

KSQ Therapeutics Appoints Chris Heberlig as Chief Financial Officer

by s2desi5_ksqtherapeutics | May 13, 2021 | Uncategorized

CAMBRIDGE, Mass., May 13, 2021– KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to systematically screen the whole genome to identify optimal gene targets for oncology and autoimmune disease, today announced the...

KSQ Therapeutics Announces First Patient Dosed in Phase 1 Study of KSQ-4279, a First-in-Class USP1 Inhibitor, in Patients with Advanced Solid Tumors

by s2desi5_ksqtherapeutics | Sep 14, 2021 | Uncategorized

CAMBRIDGE, Mass., September 14, 2021- KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically screen the whole genome in cancer and immune cells, today...

KSQ Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference

by s2desi5_ksqtherapeutics | Sep 22, 2021 | Uncategorized

CAMBRIDGE, Mass., September 22, 2021 – KSQ Therapeutics, a biotechnology company developing drugs to treat cancer and autoimmune diseases using its proprietary, integrated discovery platform to systematically screen the whole genome in cancer and immune cells, today...